2-Pyridyl compounds

Lanicemine (AZD6765) is a low-trapping NMDA receptor antagonist that was under development by AstraZeneca for the management of severe and treatment-resistant depression. Lanicemine differs from ketamine in that it is a low-trapping NMDA receptor antagonist, showing similar rapid-acting antidepressant effects to ketamine in clinical trials but with little or no psychotomimetic side effects. However, lanicemine did not meet study endpoints, and its development was terminated by AstraZeneca in 2013.

Fenyramidol (INN) or phenyramidol (BAN, USAN), trade name Cabral, is a pharmaceutical drug which acts as a muscle relaxant.

Methafurylene is an antihistamine and anticholinergic. Methafurylene is commonly used to relieve symptoms of allergies such as sneezing, itching, and runny nose (Sweetman, 2009).

Pritelivir (development codes AIC316 or BAY 57-1293) is a direct-acting antiviral drug in development for the treatment of herpes simplex virus infections (HSV). This is particularly important in immune compromised patients. It is currently in Phase III clinical development by the German biopharmaceutical company AiCuris Anti-infective Cures AG. US FDA granted fast track designation for pritelivir in 2017 and breakthrough therapy designation 2020.

Lecozotan is an investigational drug by Wyeth tested for improvement of cognitive functions of Alzheimer's disease patients. , the first Phase III clinical trial has been completed.

Chlorothen (trade name Thenclor) is an antihistamine and anticholinergic.